XML 114 R101.htm IDEA: XBRL DOCUMENT v3.22.4
Debt Obligations - Life Sciences Narrative (Details)
12 Months Ended
Aug. 08, 2022
USD ($)
Jul. 13, 2022
USD ($)
security
Jun. 27, 2022
USD ($)
Dec. 31, 2022
USD ($)
Feb. 15, 2023
USD ($)
Dec. 13, 2022
USD ($)
Life Sciences            
Debt Instrument [Line Items]            
Proceeds from issuance of debt       $ 10,000,000    
Life Sciences | Affiliated Entity            
Debt Instrument [Line Items]            
Repurchased outstanding notes payable   $ 4,500,000        
Interest cost relating to contractual interest coupon       800,000    
Life Sciences | Affiliated Entity | Bridge Loan            
Debt Instrument [Line Items]            
Face amount   10,000,000        
Lancer Capital, LLC | Affiliated Entity            
Debt Instrument [Line Items]            
Return from equity or debt financing, minimum       $ 20,000,000    
Lancer Capital, LLC | Affiliated Entity | R2 Technologies            
Debt Instrument [Line Items]            
Face amount           $ 800,000
18.00% Note due 2023 | Life Sciences | Affiliated Entity | Bridge Loan            
Debt Instrument [Line Items]            
Face amount     $ 500,000      
Debt instrument, term     90 days      
Interest rate     12.00%      
Repayments of related party debt   $ 500,000        
18.00% Note due 2023 | Lancer Capital, LLC | Affiliated Entity | R2 Technologies | Subsequent Event            
Debt Instrument [Line Items]            
Face amount         $ 500,000  
18.00% Note due 2023 | Lancer Capital, LLC | Affiliated Entity | Bridge Loan            
Debt Instrument [Line Items]            
Face amount           $ 10,000,000
Interest rate           18.00%
Borrowing rate           18.00%
Sellers' Notes | Life Sciences | Affiliated Entity | R2 Technologies            
Debt Instrument [Line Items]            
Related party transaction, rate   12.00%        
Number of tranches | security   2        
Notes Payable Tranche One | Life Sciences | Affiliated Entity            
Debt Instrument [Line Items]            
Repurchased outstanding notes payable   $ 5,000,000        
Notes Payable Second Tranche | Life Sciences | Affiliated Entity            
Debt Instrument [Line Items]            
Repurchased outstanding notes payable $ 5,000,000